NWT Influenza Program Vaccine Administration Summary 2020-2021

This Vaccine Administration Summary is a quick reference document for the health care providers (HCP) who will be administering influenza vaccination in the NWT.

All HCPs must have completed the Education Program on Immunization Competency (EPIC) before administration of vaccines in the NWT.

This document does not replace the information in the Canadian Immunization Guide or the product monograph. It is the vaccine administrator's responsibility to ensure they have reviewed the most current documents included in this influenza package and link provided below:

1. **National Advisory Committee on Immunization Canadian Immunization chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021** National Advisory Committee on Immunization Statement on Seasonal Influenza Vaccine for 2020-2021
2. **Product monographs for each of the vaccines listed (2020 formulation) Note: When there is a discrepancy between the NACI Statement and the product monograph, please follow the NACI statement.**

Product	Fluzone® Quadrivalent (QIV) Sanofi Pasteur (Available in multidose vials and in single dose prefilled syringe)	Fluzone® High-Dose (TIV) Sanofi Pasteur (single dose prefilled syringe) Preferred vaccine for those 65 years and older living in a Long Term Care Facility
Component Viruses	• A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09 - like strain • A/Hong Kong/2671/2019 (H3N2) - like strain • B/Phuket/3073/2013 - like strain (from B/Yamagata lineage) • B/Washington/02/2019 - like strain (from B/Victoria lineage)	• A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09 - like strain • A/Hong Kong/2671/2019 (H3N2) - like strain • B/Washington/02/2019 - like strain

Product	Fluzone® Quadrivalent (QIV) Sanofi Pasteur (Available in multidose vials and in single dose prefilled syringe)	Fluzone® High-Dose (TIV) Sanofi Pasteur (single dose prefilled syringe) Preferred vaccine for those 65 years and older living in a Long Term Care Facility
Type of vaccine	Inactivated split-virus	
Amount of antigen	15 micrograms per strain listed above	60 micrograms per strain listed above
Adjuvant	No	
Age Indications	Six months of age and older	65 years of age and over
Route of administration	Intramuscular	
Dose: offer each influenza season	0.5 ml	
Booster Dose	A booster dose is required at least four weeks after the first dose for those aged six months to less than nine years of age receiving the vaccine for the first time	Not required
Contraindications	***Egg allergy is no longer a contraindication for any influenza vaccine product**	
	• People who have had an anaphylactic reaction to a previous dose; or • People who have had an anaphylactic reaction to any of the vaccine components **except egg** (NACI Statement 2020/2021) • Vaccination of persons known to have had Guillain-Barré syndrome (GBS) within six weeks of a previous influenza vaccination.	

Product	Fluzone® Quadrivalent (QIV) Sanofi Pasteur (Available in multidose vials and in single dose prefilled syringe)	Fluzone® High-Dose (TIV) Sanofi Pasteur (single dose prefilled syringe) **Preferred vaccine for those 65 years and older living in a Long Term Care Facility**
Precautions: The potential risk of influenza must be balanced against the risk of vaccine administration	• Delay vaccination in persons with a serious acute illness until symptoms have abated • **Do not** delay immunization due to a minor illness with or without fever • Persons who experienced Oculo-Respiratory Syndrome (ORS) with lower respiratory track symptoms should be evaluated by an expert prior to re-vaccination with an influenza product	
Common side effects For a complete listing, refer to each vaccine's product monograph	• Pain, redness and swelling at the injection site • Headache, muscle and joint pain, fatigue, and fever • Occasionally feeling sick with diarrhea, vomiting, stomach pain • Children may also have; irritability and drowsiness • Most reactions resolve by three days	• Pain, redness and swelling at the injection site • Headache, muscle and joint pain, fatigue, and fever • Occasionally feeling sick with diarrhea, vomiting, stomach pain • Most reactions resolve by three days • May induce higher rates of systemic reactions post-injection but reactions are still mild and short-lived
Antibiotics	No	
Gelatin	No	
Egg Protein	Yes	
Non- medical ingredients	For a complete listing, refer to each vaccine's product monograph	
Thimerosal	Prefilled syringe: No Multi-dose Vial: Yes	Yes
Latex	No	

Adverse Event Following Immunization (AEFI) specific to Influenza Vaccine Product: Adverse Event Following Immunization Reporting Form

- Any serious, unexpected event or a change in frequency of a known AEFI must be reported within 24 hours of identification of the AEFI to the Office of the Chief Public Health Officer.
- An unexpected event is an event that is not listed in available product monograph but may be due to the immunization.
- Of particular interest is Guillain-Barré syndrome (GBS) within six weeks of an influenza vaccine and OculoRespiratory Syndrome (ORS) with or without respiratory symptoms.

References:

- Adverse Event Following Immunization form, Public Health Agency of Canada:
  Report of Adverse Events Following Immunization (AEFI) - Immunization & Vaccines - Public Health Agency of Canada
- National Advisory Committee on Immunization Canadian Immunization Guide Statement on Seasonal Influenza Vaccine for 2020-2021:
  National Advisory Committee on Immunization: Canadian Immunization Guide Statement on Seasonal Influenza Vaccine for 2020-2021
- Vaccine Product Monographs: https://www.hss.gov.nt.ca/professionals/content/seasonal-influenza-immunization-package
  Drug Product Database online query
  - Fluzone® Quadrivalent
  - Fluzone® High-Dose